Hemophagocytic lymphohistiocytosis

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Section editor
Ronaldgo.jpg
Ronald S. Go, MD
Mayo Clinic
Rochester, MN
4 regimens on this page
4 variants on this page


Guidelines

Histiocyte Society

  • 2019: La Rosée P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, Birndt S, Gil-Herrera J, Girschikofsky M, Jordan MB, Kumar A, van Laar JA, Lachmann G, Nichols KE, Ramanan AV, Wang Y, Wang Z, Janka G, Henter JI. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019 Apr 16. [Epub ahead of print] link to original article PubMed

"How I treat"

  • 2015: Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood. 2015 May 7;125(19):2908-14. Epub 2015 Mar 10. link to original article PubMed

Untreated

HLH-94 regimen

back to top

Regimen

Study Evidence
Henter et al. 1997 (HLH-94) Non-randomized

Immunosuppressive therapy, initial

  • Dexamethasone (Decadron) in a tapering schedule as follows:
    • Weeks 1 & 2: 10 mg/m2/day (single or split doses not specified)
    • Weeks 3 & 4: 5 mg/m2/day (single or split doses not specified)
    • Weeks 5 & 6: 2.5 mg/m2/day (single or split doses not specified)
    • Week 7: 1.25 mg/m2/day (single or split doses not specified)
    • Taper off during week 8 (exact schedule not specified)
  • Etoposide (Vepesid) as follows:
    • Weeks 1 & 2: 150 mg/m2 IV twice per week
    • Weeks 3 to 8: 150 mg/m2 IV once per week
  • Methotrexate (MTX) (dose not specified) IT once per week for weeks 3 to 6 in patients with progressive neurological symptoms and/or persisting abnormal cerebrospinal fluid findings.

Supportive medications

8-week course; patients without familial or persistent disease then stopped. Patients with familial, persistent, or relapsed disease were treated with up to one year of continuation therapy, until an allogeneic HCT could be performed, as follows:

Immunosuppressive therapy, continuation

Continued for up to 52 weeks

References

  1. HLH-94: Henter JI, Aricò M, Egeler RM, Elinder G, Favara BE, Filipovich AH, Gadner H, Imashuku S, Janka-Schaub G, Komp D, Ladisch S, Webb D; HLH study Group of the Histiocyte Society. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. Med Pediatr Oncol. 1997 May;28(5):342-7. link to original article does not contain protocol PubMed
    1. Update: Henter JI, Samuelsson-Horne A, Aricò M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, Webb D, Janka G; Histocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002 Oct 1;100(7):2367-73. link to original article contains verified protocol PubMed
    2. Update: Trottestam H, Horne A, Aricò M, Egeler RM, Filipovich AH, Gadner H, Imashuku S, Ladisch S, Webb D, Janka G, Henter JI; Histiocyte Society. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011 Oct 27;118(17):4577-84. Epub 2011 Sep 6. link to original article contains verified protocol link to PMC article PubMed

HLH-2004 regimen

Relapsed or refractory

DEP

back to top

DEP: Doxil (Liposomal doxorubicin), Etoposide, MethylPrednisolone

Regimen

Study Evidence Efficacy
Wang et al. 2015a Phase II 76%

Note: Liposomal doxorubicin could be repeated, although details are scant in the text. End of etoposide is also somewhat unclear.

Chemotherapy

One course

References

  1. Wang Y, Huang W, Hu L, Cen X, Li L, Wang J, Shen J, Wei N, Wang Z. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood. 2015 Nov 5;126(19):2186-92. Epub 2015 Aug 19. link to original article contains verified protocol link to PMC article PubMed